Charles Sternberg, Associate Editor12.15.23
Theragen, a medical technology company, has been issued two new U.S. patents and allowed a third pending U.S. patent application.
Together with two previously issued patents (U.S. 11,395,919 and 11,426), this further demonstrates Theragen’s contribution to innovation in the field of post-surgical therapeutics, patient engagement, and digital data insights.
Richard Pearce, COO and VP of R&D of Theragen, says, “These patents provide protection for the unique, differentiating elements of Theragen’s ActaStim bone growth stimulator system, which is intentionally designed to improve patient compliance and spinal fusion success.”
U.S. Patent 11,759,637, which was issued on September 19, 2023, correlates system usage with the patient’s physiology to ensure patient confidence in the ongoing treatment and encourage patient compliance with the therapy regimen.
U.S. Patent Application Publication No. 2022/0387783, which was allowed on August 30, 2023, will be issued later this year with claims of comparing patient physiological data with patient-reported outcome measures, such as post-operative pain level, and to optimize the therapy regimen using this data.
Chris McAuliffe, CEO and President of Theragen, says, “The issuance of five patents in just over two years, reflects our ongoing commitment to innovation in the field of IoT and data-driven insight generation. Our belief is that capturing, combining, and graphically displaying key recovery metrics enables patients to play an active role in their healing journey and provides Healthcare Providers a comprehensive and accurate picture of their patient’s recovery progress.”
Together with two previously issued patents (U.S. 11,395,919 and 11,426), this further demonstrates Theragen’s contribution to innovation in the field of post-surgical therapeutics, patient engagement, and digital data insights.
Richard Pearce, COO and VP of R&D of Theragen, says, “These patents provide protection for the unique, differentiating elements of Theragen’s ActaStim bone growth stimulator system, which is intentionally designed to improve patient compliance and spinal fusion success.”
About the Patents
U.S. Patent 11,717,685, which was issued on August 8, 2023, focuses on tracking the intensity level of patient activity together with device usage, comparing this data against the prescribed therapy regimen to deliver insight into the recovery process for patients and surgeons.U.S. Patent 11,759,637, which was issued on September 19, 2023, correlates system usage with the patient’s physiology to ensure patient confidence in the ongoing treatment and encourage patient compliance with the therapy regimen.
U.S. Patent Application Publication No. 2022/0387783, which was allowed on August 30, 2023, will be issued later this year with claims of comparing patient physiological data with patient-reported outcome measures, such as post-operative pain level, and to optimize the therapy regimen using this data.
Chris McAuliffe, CEO and President of Theragen, says, “The issuance of five patents in just over two years, reflects our ongoing commitment to innovation in the field of IoT and data-driven insight generation. Our belief is that capturing, combining, and graphically displaying key recovery metrics enables patients to play an active role in their healing journey and provides Healthcare Providers a comprehensive and accurate picture of their patient’s recovery progress.”